Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : LIFE save search
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
Published: 2023-06-22 (Crawled : 12:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 1.3%
H: 0.39%
C: -2.99%
drug sclerosis treatment designation grants efzofitimod
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 14:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 1.05%
H: 1.04%
C: -0.52%
atyr2810 pharma treatment tumor research preclinical meeting therapy growth
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of SarcoidosisGlobal pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe
Published: 2023-01-18 (Crawled : 18:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.0%
H: 2.45%
C: -2.18%
treatment europe designation drug grants study
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
Published: 2022-11-09 (Crawled : 15:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.0%
H: 0.21%
C: -4.62%
treatment pharma positive publication study phase 2b
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Published: 2022-09-13 (Crawled : 13:20) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.27%
H: 1.08%
C: -0.54%
treatment fda designation lung pharma disease fast track designation
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Published: 2022-08-11 (Crawled : 12:20) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 1.07%
H: 2.65%
C: -3.18%
atyr1923 treatment fda designation pharma fast track designation
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic SclerosisSecond U.S. orphan drug designation for efzofitimod clinical program
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.21%
H: 10.73%
C: 7.16%
atyr1923 treatment fda pharma drug program designation
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 3.62%
H: 6.6%
C: 2.33%
treatment fda phase 2 pos positive
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of SarcoidosisCompany expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022
Published: 2022-01-06 (Crawled : 15:30) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: -1.1%
H: 2.78%
C: -0.56%
atyr1923 treatment fda drug trial orphan drug designation
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
Published: 2021-06-23 (Crawled : 12:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: -0.9%
H: 3.88%
C: 3.2%
treatment pharma
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.